Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should be Treated at the Time of Diagnosis
Arch Neurol 63:614-619, Frohman,E.M.,et al, 2006
Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis
Arch Neurol 63:611-619, Pittock,S.J.,et al, 2006
Accuracy of Magnetic Resonance Imaging for the Diagnosis of Multiple Sclerosis: Systematic Review
BMJ 332:875-878, Whiting P.,et al, 2006
The Utility of MRI in Suspected MS, Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 61:602-611,596, Frohman,E.M.,et al, 2003
Management of Acute Optic Neuritis
Lancet 360:1953-1962, Hickman,S.J.,et al, 2002
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001
Multiple Sclerosis--From Probable to Definite Diagnosis
Arch Neurol 57:974-979,930, Achiron,A. & Barak,Y., 2000
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Diagnosis of Multiple Sclerosis: Progress and Challenges
Lancet 389:1336-1346, Brownlee, W.J.,et al, 2017
Neuromyelitis Optica: Evaluation of 871 Attacks and 1,153 Treatment Courses
Ann Neurol 79:206-216,204, Kleiter, I.,et al, 2016
Responsibilities of Health Care PRofessionals in Counseling and Educating Patients with Incurable Neurological Diseases Regarding "Stem Cell Tourism"
JAMA Neurol 72:1342-1345, Bowman, M.,et al, 2015
Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:e103-e104, Fox, R.J., 2014
Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke
NEJM 370:1091-1100,1159, Juttler, E.,et al, 2014
Should Doctors Prescribe Cannabinoids?
BMJ 348:g2737, Farrell, M.,et al, 2014
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Cerebral Sinovenous Thrombosis in the Neonate
Arch Neurol 63:405-409, Fitzgerald,K.C.,et al, 2006
Treatment of Low Back Pain by Acupressure and Physical Therapy: Randomised Controlled Trial
BMJ 332:696-698,680, Hsieh,L.L.-C.,et al, 2006
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Interferons in Relapsing Remitting Multiple Sclerosis: A Systematic Review
Lancet 361:545-552, Filippini,G.,et al, 2003
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol 58:1299-1300,1301, Pachner,A.R., 2001
The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta
Arch Neurol 58:1297-1298,1301, Rice,G., 2001
Trauma Does Not Precipitate Multiple Sclerosis
Arch Neurol 57:1077-1078, Cook.S.D., 2000
Trauma to the Central Nervous System May Result in Formation or Enlargement of Multiple Sclerosis Plaques
Arch Neurol 57:1074-1076,1078, Poser,C.M., 2000
Fibromyalgia Syndrome a Decade Later
Arch Int Med 159:777-785, Goldenberg,D.L., 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Different Predictors of Neurolgoical Worsening in Different Causes of Stroke
Arch Neurol 55:481-486, Yamamoto,H.,et al, 1998
Use of Corticosteroids in Multiple Sclerosis by Consultant Neurologists in the United Kingdom
JNNP 54:362-365, Tremlett,H.L.,et al, 1998
Interferons in the Treatment of Multiple Sclerosis,Do They Prevent the Progression of the Disease?
Arch Neurol 55:1578-1580,1583, Rice,G.&Ebers,G, 1998
Interferons Should be Used to Treat Most Patients with MS
Arch Neurol 55:1581-1583, Herndon,R.M.&Jacobs,L, 1998
Consensus and Controversy in Neurologic Practice, The Case of Steroid Treatment in Multiple Sclerosis
Arch Neurol 46:322, Menken,M., 1989
Suspicion of Multiple Sclerosis, To Tell or Not To Tell
Arch Neurol 45:441-442, Sencer,W., 1988
To Use Perfusion Imaging or Not in Patient Selection for Late Window Endovascular Thrombectomy?
Neurol 100:1039-1040, Katsanos,A.H.,et al, 2023
In Stroke, When is a Good Outcome Good Enough?
NEJM 386:1359-1361, Schwamm, L.H., 2022
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Stridor in Multiple System Atrophy
Neurol 93:630-639, Cortelli, P.,et al, 2019
Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome
JAMA Neurol 75:353-359, Martinez-Ramirez, D.,et al, 2018
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Repeated Intravenous Thrombolysis for Early Recurrent Stroke
Stroke 47:2133-2135, Kahles, T.,et al, 2016
Cervical Arterial Dissections and Association with Cervical Manipulative Therapy
Stroke 45:3156-3174, Biller, J.,et al, 2014